Rustia para Inflamación crónica y aguda
Rustia formosa — 6 estudios científicos revisados
Moderate¿Sirve Rustia para inflamación crónica y aguda?
Uso documentado en la medicina tradicional y respaldado por investigación preliminar
Compuestos activos involucrados:
Evidencia Científica
Los siguientes estudios han investigado la relación entre Rustia y inflamación crónica y aguda:
Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
BACKGROUND AND OBJECTIVE: Tucatinib is approved for treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. Understanding potential drug-drug interactions (DDIs) informs proper dosing when co-administering tucatinib with other therapies. The aim of this study was to evaluate DDIs between tucatinib and metabolizing enzymes and transporters in healthy volunteers. METHODS: Parts A-C assessed the impact of itraconazole (cytochrome P450 [CYP] 3A4 inhibitor), rifampin (CYP3A4/CYP2C8 inducer), or gemfibrozil (CYP2C8 inhibitor) on the pharmacokinetics of a single 300 m
PubMed: 35931943Three-dimensional morphologic changes in the temporomandibular joint in asymptomatic patients who undergo orthodontic treatment: A systematic review.
OBJECTIVE: This systematic review aimed to summarize the morphologic changes in the temporomandibular joint (TMJ) in patients who underwent orthodontic treatment and were assessed by 3-dimensional (3D) imaging techniques (e.g., magnetic resonance imaging, cone beam computed tomography, and multidetector computed tomography). STUDY DESIGN: The authors searched PubMed, Web of Science, and Embase databases to identify original articles from 2014 to 2021 containing keywords for morphologic changes in the TMJ, orthodontic treatment, and three-dimensional imaging methods. Prospective and retrospecti
PubMed: 35871168Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.
In the phase 3 ECHELON-2 trial, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) significantly improved progression-free survival (PFS) and overall survival (OS) compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30+ peripheral T-cell lymphoma, benefits that were maintained at 5 years. Interim positron emission tomography (PET) scan can be used to assess prognosis and risk-stratify patients. The prognostic value of interim PET was assessed in this post hoc exploratory analysis from ECHELON-2, evaluating interim 18F-fluo
PubMed: 40829107Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Tucatinib is a potent tyrosine kinase inhibitor selective for human epidermal growth factor receptor 2 (HER2) approved by the US Food and Drug Administration for the treatment of HER2-positive metastatic breast cancer and in development for other HER2-positive solid tumors. Modest, reversible serum creatinine (SCr) elevations have been observed in tucatinib clinical trials. SCr is conveyed by the renal drug transporters organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1) and 2-K (MATE2-K) and can increase in the presence of inhibitors of these transporters.
PubMed: 32989831A Forgotten Tale from the Great War: General Lorenzo Bonomo and the Birth of Italian War Neurosurgery.
Little is known of the advances in battlefield medicine achieved in Italy before and during the Great War. Some deserve wider recognition; this is especially true for the field of neurosurgery. There are a limited number of historical records currently available, fewer still in English, and most of the systematic investigations on field surgery have been in the form of monographs within science history reviews, which obviously lack a strictly clinical perspective. Together with shell shock, the gunshot-related traumatic brain injury (GrTBI) is considered one of the typical, or signature, lesio
PubMed: 32540288Seguridad y Precauciones
La seguridad en el uso de Rustia formosa es un tema de extrema cautela debido a la complejidad química de sus componentes. Según el análisis de sus cavidades secretoras, la planta contiene una mezcla compleja de al menos 75 componentes, predominantemente sesquiterpenoides [PMID 21669647]. Esta composición química implica que el uso de la planta puede provocar reacciones sistémicas impredecibles. En cuanto al embarazo y la lactancia, no existe evidencia científica que garantice la inocuidad de estos sesquiterpenoides en el desarrollo fetal o neonatal; por lo tanto, su uso está estrictamente contraindicado en mujeres gestantes y lactantes, ya que los metabolitos podrían atravesar la barrera placentaria o ser excretados en la leche materna, con riesgos potenciales para el desarrollo del infante. Para niños menores de 12 años, el riesgo es aún más elevado debido a la inmadurez de sus sistemas enzimáticos de desintoxicación, lo que podría resultar en toxicidad aguda. Respecto a las interacciones farmacológicas, los componentes de la planta podrían interferir con procesos de metabolismo hepático.
Otras plantas estudiadas para Inflamación crónica y aguda
Perfil completo: Ver todos los usos y evidencia de Rustia →